KRMD — KORU Medical Systems, Inc.

KORU Medical Systems (KRMD) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Achieved $10 million in revenue for the second consecutive quarter, marking a 27% year-over-year growth. The core subcutaneous immunoglobulin (SCIG) business grew by 30%.
• Gross Profit: Increased by 21% year-over-year, with a gross margin of 60.2%, down from 63.4% due to higher manufacturing costs and tariff impacts.
• Adjusted EBITDA: Positive adjusted EBITDA reported, reflecting a 109% improvement year-to-date.
• Cash Position: Ended the quarter with $8.5 million in cash, generating $400,000 in cash flow.
• Year-to-Date Revenue: Total revenue of $30.2 million, up 22% from $24.8 million in the prior year.

2. Strategic Updates and Business Highlights

• Pipeline Expansion: Announced two new collaborations in the pharmaceutical services and technology (PST) sector, focusing on expanding the product pipeline and patient populations.
• Oncology Market Entry: Completed a successful US-based oncology study, validating the FreedomEdge infusion system, with plans for a 510(k) filing by early 2026.
• International Growth: International revenue grew by 230%, with market share in the international SCIG market increasing from 10% to 20%. The company is targeting further growth through prefilled syringe conversions.
• Collaborations: Seven active collaborations with major immunoglobulin manufacturers, driving growth and geographic expansion.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised full-year revenue guidance to $40.5 million - $41 million, representing 20% to 22% growth.
• Gross Margin Guidance: Reiterated gross margin expectations of 61% to 63% for the full year.
• 2026 Outlook: While not providing specific guidance, management indicated confidence in achieving revenue growth starting with a number in the "2" (indicating over $20 million).

4. Bad News, Challenges, or Points of Concern

• Domestic Revenue Decline: Domestic revenues declined by 5% due to inventory adjustments by a US distributor, which temporarily impacted order volumes.
• Gross Margin Pressure: The gross margin decreased due to higher manufacturing costs and a shift in geographic mix, with international sales having lower average selling prices (ASPs).
• Delayed Collaborations: Two previously announced collaborations have pushed their launch dates into 2027, although this is not expected to materially impact current revenue projections.

5. Notable Q&A Insights

• Oncology Feedback: Positive nurse feedback from the oncology pilot study indicated improved workflow efficiency, with 70% of nurses able to multitask during drug administration.
• Reimbursement Structure: Current reimbursement codes for oncology infusion clinics are favorable, requiring no additional work for KORU.
• Market Dynamics: The underlying rate of patient diagnoses is increasing, with expectations for growth driven by aging populations and rising incidences of secondary immunodeficiency (SID).
• Geographic Dynamics: Management clarified that the $1.2 million adjustment in revenue was due to cross-border distributor dynamics, which have been corrected to prevent future occurrences.

Overall, KORU Medical Systems demonstrated strong growth and strategic advancements in Q3 2025, despite facing some challenges in domestic revenue and gross margin pressures. The company remains optimistic about future growth opportunities, particularly in international markets and oncology.